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We investigated the effects of herbal extracts, a mixture of Scutellariae Radix and Platycodi Radix containing the active ingredients
Baicalin and Saponin (target herbal ingredient (THI)),on lowering body weight. The present study was a prospective, randomized,
double-blind, and placebo-controlled trial carried out at the outpatient department of a hospital over a period of 2 months. Group
1p a t i e n t s( 𝑛=3 0 ) received THI, and group 2 patients (𝑛=2 3 ) received placebo three times a day before meals. Weight, waist
circumference, BMI, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and glucose were measured at baseline and
again at the 2nd month. For safety evaluation, various hematological and biochemical parameters were assessed. Values of mean
changeofweightintheTHI-treatedgroupwere−1.16±1.41kgandintheplacebo-treatedgroupwere−0.24±1.70kg,respectively.
ThedifferenceinmeanchangeofweightintheTHI-treatedgroupcomparedwiththatintheplacebo-treatedgroupwasstatistically
significant (𝑃 < 0.05). The incidence of subjective and objective adverse drug reactions was insignificant (𝑃 > 0.05). THI was
statistically significant in its effectiveness on the weight loss.
1. Introduction
Overweight or obesity substantially raises a patient’s risk of
morbidity from hypertension [1, 2], type 2 diabetes [3, 4],
dyslipidemia [5], cardiovascular disease (CVD) [5], stroke
[6], gallbladder disease [7], osteoarthritis [8], sleep apnea,
respiratory problems [9, 10], and also endometrial, breast,
prostate,andcoloncancers[11].Overweightandobesityarea
majorpublichealthconcernnotonlyinwesterncountriesbut
also in Asian countries because of its increasing prevalence
and its association to morbidity and mortality [12, 13]. The
prevalence of obesity (body mass index (BMI) ≥ 30kg/m
2)
in USA was 32.2% in 2004 [14]. While the prevalence of
obesityinAsianpopulationsislowerthanthatofCaucasians,
the health risks associated with obesity occur at a lower
BMI. Accordingly, the criteria for overweight and obesity
in the Asian-Pacific region of WHO has been proposed as
BMI ≥ 23kg/m
2 and BMI ≥ 25kg/m
2,r e s p e c t i v e l y[ 15]. The
prevalenceofobesityusingaBMI≥25kg/m
2 amongKoreans
over age 19 was 30.8% in 2010 [16] which represented a rapid
increase in comparison to rates in 1998 [17].
There is strong evidence that weight loss in overweight
and obese individuals reduces risk factors for diabetes and
cardiovasculardisease.Strongevidenceexiststhatweightloss
reduces blood pressure in both overweight hypertensive and
nonhypertensive individuals, reduces serum triglycerides,
increases high-density lipoprotein (HDL) cholesterol, and
generally produces somereductionin totalserum cholesterol
and low-density lipoprotein (LDL) cholesterol. Weight loss
reducesbloodglucoselevelsinoverweightandobesepersons
withoutdiabetes;weightlossalsoreducesbloodglucoselevels
and HbA1c in some patients with type 2 diabetes. Although
t h e r eh a v eb e e nn op r o s p e c t i v et r i a l st os h o wc h a n g e si n
mortality with weight loss in obese patients, reductions
in risk factors would suggest that development of type 2
diabetes and CVD would be reduced with weight loss [18].2 Evidence-Based Complementary and Alternative Medicine
Therefore, drugs or supplements to help weight loss need to
be developed.
This study is aimed at investigating the body weight low-
eringeffectofextractsfromamixtureofherbswiththeactive
ingredients Baicalin and Saponin (target herbal ingredient
(THI)). Baicalin is the active ingredient in Scutellariae Radix
(the root of Scutellariae baicalensis)w h i c hh a sb e e ns h o w n
to be efficacious in reducing weight, visceral fat mass, serum
cholesterol, free fatty acid, and insulin concentrations on
high-fatdiet-fedratsincomparisontocontrols[19].High-fat
diet-fed rats were also shown to suppress expected increases
in body weight [20, 21], plasma triacylglycerols, adipose
tissues [20, 22], food consumption, expression of leptin, and
neuropeptide Y [21] and prevented hepatic steatosis [22]
after consuming saponin isolated from ginseng or Platycodi
Radix. The present study was a prospective, randomized,
double-blind, and placebo-controlled trial carried out at an
outpatient department of the hospital over a period of 2-
months.
2. Materials and Methods
2.1. Study Subjects. Subjects who participated in the study
were all healthy volunteers who were recruited using
announcements in leaflets and posters at Chung-Ang Uni-
versity Hospital, Seoul, Korea. The study was approved by
the Institutional Review Board (IRB) of the Chung-Ang
University Hospital (Ethics Committee reference number
C2010114 (410)). In addition, written informed consent was
obtained from all subjects before initiation of the trial.
From November 2010 to December 2010, a total of
80 patients visited the Outpatient Department of Family
M e d i c i n eo fC h u n g - A n gU n i v e r s i t yH o s p i t a lw h e r et h e yh a d
a baseline clinical examination (weight, BMI, body and com-
position) and laboratory investigations. Body composition
was assessed by a bioelectrical impedance analysis system
( I n Bo d y7 2 0 ,B i o s p a c eCo . ,Se o u l ,K o r e a )t h a tw a sd e v e l o p e d
for the Korean population.
2.2. Inclusion and Exclusion Criteria. The inclusion criteria
were patients with BMI ≥ 23kg/m
2 of either sex between
t h ea g eo f1 8a n d7 0y e a r s .Th ef o l l o w i n gc a t e g o r i e so f
patientswereexcluded:patientswithendocrinologicobesity;
patientsusingothermedicationsthatcanalterbodyweightor
lipid levels; patients with clinically significant cardiovascular,
respiratory, or hepatobiliary disorder; chronic diarrhea; and
pregnant or lactating women.
2.3. Preparation of Herbal Dietary Supplement. The dietary
supplement, THI, was a liquid herbal extract of Scutellariae
Radix and Platycodi Radix as its main ingredient. The two
herbs were extracted and made into a dietary supplement
by Namil Farm & Ginseng Co. (Geumsam, Korea). The
two herbs were mixed at a 1:1 ratio and extracted with
7 0 %e t h a n o l .Th ee t h a n o lw a st h e ne v a p o r a t e du n d e rl o w
pressure conditions. The final yield of the herbal extract to
raw herbs was 25% (w/w). For the standardization of the
herbal extract, the contents of Baicalin—an ingredient of
Scutellariae Radix—and Saponin—an ingredient of Platy-
codi Radix—were measured using high performance liquid
chromatography resulting in 5.16% of Baicalin and 3.95% of
Saponin (w/w). The preclinical study of this herbal extract
wasreportedpreviously[22].EachpouchofTHIsupplement
contained 2.28gm of herbal extract as its main ingredient,
3.18gm of oligosaccharide as a sweetener, and 0.05gm of
b e r r yfl a v o ra n dw a sa d j u s t e dt ot h efi n a lv o l u m eo f5 0m L
with water. Placebos, with no herbal extract, contained same
sweeter and flavor to have a similar appearance and scent.
2.4. Sample Size. There were no previous studies on the
efficacy of THI with respect to body weight lowering effects
for healthy overweight humans. We postulated that we would
needasamplesizeof𝑛≥3 6inordertoseestandarddeviation
and difference of body weight change between groups with
a statistical significance level of 0.05 and power of test of 0.9
basedonpreviousanimalstudy[23].Thereforeitwasdecided
toenroll60subjectsinthestudyanticipatinga40%exclusion
from the study.
Initially, 69 subjects were enrolled in the study. Fifteen
subjects were either disqualified for not complying with the
drug regimen or voluntarily dropped from the study. One
subject was excluded for excessive exercise. A final sample
size of 𝑛=5 3was used in the final analysis and reported in
the results.
2.5. Methods and Statistics. At o t a lo f6 9p a t i e n t sw e r e
enrolledinthestudyaccordingtoinclusionandexclusioncri-
teria and were randomized into two groups of 39 patients for
THI and 30 patients for placebo on the computer-generated
listbySASrandomizationprogramatChung-AngUniversity,
College of Medicine, Department of Microbiology. Group 1
patients received THI three times a day before meals. Group
2 patients received placebo three times a day before meals.
After enrollment into the study, tests were carried out for
baseline clinical examination (weight, BMI, body composi-
tion (muscle (kg), fat (kg), and fat ratio (%)), and blood
pressure) and laboratory investigations; hematological tests
(red blood cell count, hemoglobin level, (Hb), hematocrit
level, white blood cell count, differential white blood cell
count, and blood platelet count); blood biochemical tests
(total protein, albumin, total cholesterol, HDL cholesterol,
LDLcholesterol,triglycerides,bloodureanitrogen,uricacid,
serum creatinine, aspartate transaminase (SGOT), alanine
transaminase (SGPT), 𝗾-glutamyl transpeptidase (𝗾GTP),
andbloodglucose);urineanalysis(urineprotein,urinesugar,
and urinary sediment (erythrocytes, leukocytes, and casts));
and Serologic tests (highly sensitive C-reactive protein (hs-
CRP), thyroid stimulating hormone (TSH), and free T4)). In
t h es a m ev i s i t ,i r r e s p e c t i v eo fg r o u pa l l o t t e d ,a l lt h ep a t i e n t s
were educated about the importance of lifestyle changes
including healthy dietary habits and exercise in weight
reduction and maintenance. Patients were given information
about the nutritional value of various foods and few simple
exercises for decreasing and maintaining near-normal body
weight by a clinical dietician. Their compliance for lifestyle
change advice was checked through verbal questions atEvidence-Based Complementary and Alternative Medicine 3
each visit. Biochemical examinations assessed were above
laboratory investigations (hematological tests, lipid profile,
liver function test, blood glucose, serum creatinine, urine
analysis, etc.) at baseline, the 1st month, and the 2nd month
of study period. The efficacy of the drug was assessed by
primary efficacy parameters, that is, body weight (kg), BMI
(kg/m
2), waist circumference (in cm measured at midpoint
between the lower border of rib cage and iliac crest), and
body composition. Other parameters assessed were total
cholesterol (mg/dL), triglyceride (mg/dL), LDL cholesterol
(mg/dL), HDL cholesterol (mg/dL), random blood glucose
level (mg/dL), hs-CRP (mg/L), and blood pressure (mmHg).
Safety was assessed in terms of both subjective and objective
adverse effects with grading scale of Common Terminology
Criteria for Adverse Events v3.0 (CTCAE) [24]. Subjective
symptomssuch asanorexia,nausea,indigestion,loosestools,
and constipation were assessed by questioning patients at
each visit. Objective signs were assessed by clinical and
biochemical examination. Followups were performed at the
1st and 2nd months of the study period, and during each
visit, all the efficacy parameters were measured, and safety
evaluations were done.
Quantitative data was analyzed by 𝑡-test or Mann-
Whitney 𝑈-test for the differences between two means, while
qualitative data was analyzed by Chi-square test or Fisher’s
exact test for difference between two proportions. 𝑃 value <
0.05 was taken as significant, while 𝑃 value > 0.05 was taken
as insignificant.
Analyses were performed using the SPSS statistical soft-
ware Version 12.0KO for windows (SPSS Inc.).
3. Results
Nine patients withdrew from trial in the THI-treated group,
and 6 patients withdrew from trial in the placebo-treated
group because they were busy and had been taking their
supplements irregularly.No patientswithdrewdue toadverse
effects of the supplements. In the placebo-treated group, one
male patient was excluded because, unlike the rest of the
patients, he exercised over 2 hours a day which was too
vigorous for the purpose of this study.
At the time of the final analysis, there were 30 patients in
the THI-treated group and 23 patients in the placebo-treated
group.
Baseline values of both groups were comparable with
respect to age, sex, weight, height, BMI, waist circumfer-
ence, hip circumference, blood pressure, and laboratory
investigations (random blood glucose level, total cholesterol,
triglyceride,HDLcholesterol,LDLcholesterol,etc.)(Table 1).
There were insignificant differences between the two groups
except the total bilirubin level (𝑃 < 0.05).
IntheTHI-treatedgroup,themeanweightatbaselinewas
71.84 ± 10.57kg and reduced to 70.68 ± 10.25kg 2-months
later. In the placebo-treated group, mean weight at baseline
was 67.89 ± 7.85kg and reduced to 67.64 ± 7.96kg after 2-
months.
Whenthemeanvalueofthechangeofweigh tintheTHI-
treated group was compared with that in the placebo-treated
group, it was found that the difference in mean change of
weightwasstatisticallysignificant(𝑃 < 0.05)(Table 2).When
values of the mean change of the other clinical examination
variables in the THI-treated group were compared with that
intheplacebo-treatedgroup,thedifferenceswerefoundtobe
statistically insignificant (𝑃 > 0.05).
There were no significant (𝑃 > 0.05) differences in the
mean change of blood glucose level, total cholesterol con-
centration, triglyceride concentration, HDL cholesterol con-
centration, LDL cholesterol concentration, hs-CRP level, and
systolic and diastolic blood pressure during the 2-month
treatmentintheTHI-treatedgroupcomparedtotheplacebo-
treatedgroup(Table 2).Allchangedlaboratoryinvestigations
were in normal range.
In the present study, the incidence of adverse drug
reactionslikenausea(16.7%),indigestion(26.7%),abdominal
pain (3.3%), loose stools (6.7%), diarrhea (13.3%), constipa-
tion (6.7%), insomnia (6.7%), itching (6.7%), satiety (6.7%),
suppressionofappetite(10.0%),andsoforthwasinsignificant
in the THI-treated group compared to the placebo-treated
group (𝑃 > 0.05)( Table 3). Most of these adverse effects
weremildandtransient.THIhadnoadverseimpactonwhite
blood cell count, hemoglobin, red blood cell count, hema-
tocrit, platelet count, total protein, albumin, total bilirubin,
direct bilirubin, SGOT, SGPT, 𝗾GTP, blood urea nitrogen,
serum creatinine, uric acid, TSH, and free T4 level at the end
of study (Table 2).
4. Discussion
A sedentary lifestyle coupled with an increased intake of
energy-dense food is contributing to the increased preva-
lence of obesity worldwide. A range of strategies can be
employed for weight loss which includes lifestyle changes
(diet, exercise), behavioral therapy, pharmacotherapy, and
surgery. Orlistat is an effective and well-tolerated antiobesity
drug, which can be employed as an adjunct to therapeutic
lifestylechangestoachieveandmaintainoptimalweight[25].
B u tm o s ta n t i o be s i t yd ru g sa cto nt h ec e n t r a ln e rv o u ss y s t e m
to suppress appetite, reduce food intake, and have serious
adverse effects. Therefore, alternative drugs or supplements
to help weight loss need to be developed.
In traditional medicine of East Asian countries includ-
ing China, Korea, and Japan, Scutellariae Radix extracts
are widely used for clinical treatment of hyperlipemia,
atherosclerosis, hypertension, dysentery, the common cold,
andinflammatorydiseasessuchasatopicdermatitis.Baicalin,
5,6-dihydroxyflavone-7-glucuronicacid,isamajorflavonoid
found in Scutellariae Radix and is well known for its anti-
inflammatory and antioxidant activities [26, 27], and few
reports describe the antiobesity effects of this compound. In
vitro study, Baicalin treatment of 3T3-L1 preadipocytes was
s h o w nt oi n h i b i tt r i g l y c e r i d ea c c u m u l a t i o na n dl i p i dd r o p l e t
formation during induced adipogenesis. Baicalin inhibits
adipogenesis through the downregulation of proadipogenic
genes, including PPAR𝗾,C / E B P 𝗼, and KLF15, as well as the
upregulation of antiadipogenic regulators, including C/EBP𝗾
and KLF2 [28]. Also in animal studies, Baicalin might have4 Evidence-Based Complementary and Alternative Medicine
Table 1: General characteristics of study subjects.
Variables THI Placebo 𝑃 value
(𝑛=3 0 )( 𝑛=2 3 )
Sex
Male 3 (10) 5 (21.7) 0.272
Female 27 (90) 18 (78.3)
Age (years) 42.90 ± 12.67 41.83 ± 14.82 0.778
Height (cm)
∗ 159.22 ± 7.91 160.03 ± 9.46 0.654
Weight (kg) 71.84 ± 10.57 67.89 ± 7.85 0.139
Body mass index (kg/m
2) 28.35 ± 3.95 26.51 ± 2.21 0.050
Waist circumference (cm) 84.02 ± 8.66 82.96 ± 6.61 0.628
Hip circumference (cm)
∗ 102.79 ± 7.09 99.40 ± 3.97 0.337
Waist/hip (%) 81.75 ± 6.51 83.50 ± 6.28 0.329
Body composition
Muscle (kg)
∗ 42.60 ± 7.91 41.14 ± 8.07 0.355
Fat (kg) 26.68 ± 7.94 24.43 ± 4.24 0.225
Fat ratio (%) 36.90 ± 7.81 36.28 ± 6.48 0.759
Blood pressure (mmHg)
Systolic 124.80 ± 13.66 125.17 ± 13.58 0.922
Diastolic
∗ 85.47 ± 10.18 84.74 ± 9.79 0.842
Blood glucose (mg/dL)
∗ 94.73 ± 11.43 96.00 ± 6.19 0.570
Total cholesterol (mg/dL) 197.20 ± 38.39 201.39 ± 39.83 0.700
Triglyceride (mg/dL)
∗ 115.03 ± 76.11 117.57 ± 56.93 0.341
HDL cholesterol (mg/dL)
∗ 49.97 ± 9.04 54.04 ± 12.55 0.261
LDL cholesterol (mg/dL) 117.67 ± 31.76 115.91 ± 28.30 0.836
hs-CRP (mg/L)
∗ 0.92 ± 0.88 2.41 ± 6.52 0.495
White blood cell count (10
∧9/L)
∗ 5.99 ± 1.37 6.72 ± 1.56 0.097
Hemoglobin (g/dL) 13.69 ± 1.23 14.11 ± 1.42 0.262
Hematocrit (%)
∗ 41.03 ± 3.25 42.22 ± 3.65 0.274
Platelet count (10
∧9/L)
∗ 256.97 ± 43.91 255.87 ± 45.20 0.641
Total protein (g/dL) 7.26 ± 0.25 7.42 ± 0.42 0.091
Albumin (g/dL)
∗ 4.32 ± 0.25 4.36 ± 0.25 0.562
Total bilirubin (mg/dL)
∗ 0.58 ± 0.16 0.74 ± 0.29 0.029
‡
Direct bilirubin (mg/dL)
∗ 0.17 ± 0.05 0.21 ± 0.08 0.091
SGOT (IU/L)
∗ 23.10 ± 7.22 21.30 ± 5.49 0.335
SGPT (IU/L)
∗ 25.77 ± 14.86 22.17 ± 13.00 0.243
𝗾GTP (IU/L)
∗ 32.53 ± 29.19 24.65 ± 15.08 0.596
Blood urea nitrogen (mg/dL)
∗ 13.33 ± 3.16 13.70 ± 3.75 0.704
Serum creatinine (mg/dL)
∗ 0.79 ± 0.16 0.83 ± 0.12 0.332
Uric acid (mg/dL)
∗ 4.31 ± 1.03 4.57 ± 1.49 0.713
TSH (mIU/mL)
∗ 2.23 ± 1.58 1.95 ± 1.19 0.634
Free T4 (ng/dL)
∗ 1.08 ± 0.19 1.10 ± 0.14 0.389
Chi-square test (categorical variables); 𝑡-test (continuous variables); ∗𝑃 value using Mann-Whitney 𝑈-test; ‡𝑃 < 0.05.
Values given are number of patients (%) or mean ± SD.
LDL: low-density lipoprotein; HDL: high-density lipoprotein; hs-CRP: highly sensitive C-reactive protein; SGOT: aspartate transaminase; SGPT: alanine
transaminase; 𝗾GTP: 𝗾-glutamyltranspeptidase; TSH: thyroid stimulating hormone.
beneficial effects on the development of hepatic steatosis and
obesity-relateddisordersbytargetingthehepaticAMPK[19].
Platycodi Radix has long been used as an expectorant
in traditional oriental medicine. Recently, it was reported
that Platycodi Radix has anti-inflammatory, antiallergy, anti-
tumor, apoptosis-inducing, and immune-stimulating activ-
ities [29–31]. Recently, it was reported that platycodin D,
a major saponin component of Platycodi Radix, inhibits fat
accumulation and adipogenesis [22, 32–35]. The antiobesity
effect of the crude saponins in mice fed a high-fat diet
may be due to the inhibition of intestinal absorption of
dietary fat by platycodin D [22]. And the antiadipogenic
effect of platycodin D involves the upregulation of KLF2 and
subsequent downregulation of PPAR𝗾 [36].Evidence-Based Complementary and Alternative Medicine 5
Table 2: Changes over time in clinical examination and laboratory investigations between THI and placebo ingestion groups.
Variables THI Placebo 𝑃 value
(𝑛=3 0 )( 𝑛=2 3 )
Weight (kg) −1.16 ± 1.41 −0.24 ± 1.70 0.036
‡
Body mass index (kg/m
2) −0.41 ± 0.55 −0.10 ± 0.70 0.083
Waist circumference (cm)
∗ −1.77 ± 1.91 −1.04 ± 2.38 0.156
Hip circumference (cm) −1.23 ± 1.77 −0.71 ± 1.78 0.304
Waist/hip (%) −0.77 ± 2.23 −0.46 ± 2.32 0.628
Body composition
Muscle (kg)
∗ −0.63 ± 1.51 −0.06 ± 0.98 0.151
Fat (kg) −0.50 ± 1.36 −0.38 ± 1.47 0.761
Fat ratio (%)
∗ −0.06 ± 1.82 −0.41 ± 1.36 0.957
Blood pressure (mmHg)
Systolic
∗ −11.30 ± 13.92 −5.65 ± 16.29 0.368
Diastolic −8.20 ± 10.60 −6.00 ± 11.07 0.466
Blood glucose (mg/dL)
∗ −1.93 ± 8.05 1.43 ± 7.26 0.062
Total cholesterol (mg/dL) −4.63 ± 26.84 −9.73 ± 24.23 0.478
Triglyceride (mg/dL)
∗ −14.96 ± 59.22 1.43 ± 48.64 0.647
HDL cholesterol (mg/dL)
∗ 3.50 ± 16.99 −2.39 ± 8.47 0.124
LDL cholesterol (mg/dL)
∗ −3.50 ± 30.39 −3.56 ± 20.53 0.628
hs-CRP (mg/L)
∗ 1.59 ± 6.25 −1.36 ± 6.50 0.251
White blood cell count (10
∧9/L) −0.13 ± 1.02 −0.42 ± 1.07 0.328
Hemoglobin (g/dL)
∗ −0.12 ± 0.51 0.73 ± 5.24 0.208
Hematocrit (%)
∗ −2.09 ± 7.30 −1.43 ± 1.11 0.258
Platelet count (10
∧9/L) −14.50 ± 23.21 −5.65 ± 29.32 0.226
Total protein (g/dL)
∗ −0.15 ± 1.31 0.00 ± 0.29 0.240
Albumin (g/dL)
∗ 0.04 ± 0.14 0.02 ± 0.17 0.483
Total bilirubin (mg/dL)
∗ 0.04 ± 0.14 0.00 ± 0.33 0.112
Direct bilirubin (mg/dL)
∗ 0.01 ± 0.06 0.01 ± 0.12 0.568
SGOT (IU/L)
∗ −0.26 ± 6.20 −0.60 ± 3.47 0.971
SGPT (IU/L)
∗ −0.73 ± 10.41 −1.13 ± 5.40 0.869
𝗾GTP (IU/L)
∗ −1.26 ± 7.65 1.17 ± 12.64 0.487
Blood urea nitrogen (mg/dL)
∗ −1.43 ± 2.80 −1.52 ± 3.96 0.474
Serum creatinine (mg/dL)
∗ 0.03 ± 0.10 0.00 ± 0.05 0.223
Uric acid (mg/dL)
∗ −0.09 ± 0.59 −0.10 ± 0.63 0.621
TSH (mIU/mL)
∗ 0.13 ± 1.45 −0.14 ± 1.15 0.680
Free T4 (ng/dL)
∗ 0.08 ± 0.35 0.07 ± 0.31 0.634
𝑡-test;
∗𝑃 value using Mann-Whitney 𝑈-test;
‡𝑃 < 0.05.
Values given are number of patients (%) or mean ± SD.
LDL: low-density lipoprotein; HDL: high-density lipoprotein; hs-CRP: highly sensitive C-reactive protein; SGOT: aspartate transaminase; SGPT: alanine
transaminase; 𝗾GTP: 𝗾-glutamyltranspeptidase; TSH: thyroid stimulating hormone.
I no u rs t u d y ,v a l u e so fm e a nc h a n g eo fw e i g h td u r -
ing the 2-month treatment in the THI-treated group were
−1.16 ± 1.41k ga n di nt h ep l a c e b o - t r e a t e dg r o u pw e r e
−0.24 ± 1.70kg, respectively. When the mean change in
weight in the THI-treated group was compared with that in
the placebo-treated group, it was found that the difference
i nt h em e a nc h a n g eo fw e i g h tw a ss t a t i s t i c a l l ys i g n i fi c a n t
(𝑃 < 0.05), but the mean change of weight during the
2-month treatment in the THI-treated group was −1.16 ±
1.41kg. Caloric restriction combined with exercise or alone
to create a daily energy deficit is the foundation of most
weight loss programs. In these programs, many individuals
successfully lose at least 4.5Kg of body weight through
behavioralapproachesfor6months[36].Inotherstudies,the
placebo-treated group loses at least −1.49 ± 6.19kg of body
weight during the 2-months [25] .S oc a nw ec o n c l u d ef r o m
our study that THI was effective in weight loss?
Our study was conducted in South Korea between
Novemberof2010toFebruaryof2011,whenmostKoreanseat
and drink more than usual. In addition, the winters in Korea
frequently have heavy snowstorms, so our patients did not
exercise properly around the time we were completing our6 Evidence-Based Complementary and Alternative Medicine
Table 3: Side effects during treatment of THI and placebo.
Side effects THI Placebo 𝑃 value
(𝑛=3 0 )( 𝑛=2 3 )
Anorexia grade 1
∗ 0 1 (4.3) 0.434
Nausea grade 1 5 (16.7) 1 (4.3) 0.217
Indigestion grade 1 8 (26.7) 3 (13.0) 0.313
Hunger pain grade 1 1 (3.3) 0 1.0
Abdominal pain grade 1 1 (3.3) 0 1.0
Loose stool grade 1 2 (6.7) 3 (13.0) 0.642
Diarrhea grade 1 4 (13.3) 1 (4.3) 0.374
Constipation grade 1 2 (6.7) 1 (4.3) 1.0
Facial edema grade 1 1 (3.3) 0 1.0
Headache grade 1 1 (3.3) 0 1.0
Insomnia grade 1 2 (6.7) 1 (4.3) 1.0
Itching grade 1 2 (6.7) 0 0.499
Fatigue grade 1 1 (3.3) 1 (4.3) 1.0
Palpitation grade 1 0 1 (4.3) 0.434
Satiety grade 1 2 (6.7) 2 (8.7) 1.0
Relieve constipation grade 1 5 (16.7) 4 (17.4) 1.0
Good appetite grade 1 1 (3.3) 1 (4.3) 1.0
Increased gastric acid secretion grade 1 1 (3.3) 0 1.0
Suppression of appetite grade 1 3 (10.0) 4 (17.4) 0.451
Thirst grade 1 1 (3.3) 0 1.0
Chi-square test;
∗𝑃 value using Fisher’s exact test.
Values given are number of patients (%).
Grading scale of Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
study. In our study, even though weight loss was small, THI
was statistically significant in its effectiveness on the weight
loss.
Prior to this study, THI improved metabolic abnormality
in mice that were fed high-fat diets [23]. And the extracts
of Platycodi Radix with white balloon flower ameliorated
obesityandinsulinr esistanceinobesemiceviatheactiva tion
of AMPK/ACC pathways and reductions of adipocyte differ-
entiation. It also reduced the elevated circulating mediators,
including triglyceride, total cholesterol, leptin, resistin, and
monocyte chemotactic protein- (MCP-) 1 in obesity [37].
Therefor we expected that THI improved metabolic
abnormality with body weight loss in our study. In our
study, the values of mean change of triglyceride and HDL
cholesterol during the 2-month treatment in the THI-treated
g r o u ps e e m e dt ob ei m p r o v e dt h a nt h o s ei nt h ep l a c e b o -
treated group. However, those were not statistically signif-
icant (𝑃 > 0.05), because the remedy was a supplement,
not a medication, the group was small, the study period was
short, and the body reduction effect was too small. We will,
therefore,needfurtherresearchinordertomakeconclusions
about its long-term effects.
However, in our study, values of mean change of platelet
count during the 2-month treatment in the THI-treated
group seemed to be decreased than that in the placebo-
treated group. But, that was not statistically significant (𝑃>
0.05).Scuttellariahasantithromboticandantiplateletactions
that prevent the pathological changes of atherosclerosis
and restenosis because it has several chemical compounds.
Baicalin has antiproliferative and lipoxygenase-inhibitory
activities [38], and Oroxylin A has antithrombotic activities
[39]. Also there was a protective effect from Scutellaria
baicalensis Georgi on cerebral ischemia injury [40]. So if we
studied for a longer time, the result would be statistically
significant, and the side effect of bleeding tendency would
occur. But in our study the change occurred in normalrange.
The adverse drug reactions were indigestion (26.7%),
nausea(16.7%),diarrhea(13.3%),andloosestool(6.7%).They
were mainly gastrointestinal symptoms. These adverse drug
reactions may have been due to the body weight lowering
effects of the crude saponins, the inhibition of pancreatic
lipase activity and intestinal absorption of dietary fat by
platycodin D [28]. However, patients who suffered from
constipation before the study began felt that the supple-
ment relieved their constipation (16.7%). In our study, the
incidence of subjective and objective adverse drug reactions
was insignificant in the THI-treated group compared to the
placebo-treated group (𝑃 > 0.05).
We could not make a capsule or tablet for this study
because the THI supplements were 50mL of liquid extracts.
There can, therefore, be problems for long-term storage.
5. Conclusion
In conclusion, the herb extract, a mixture of Scutellariae
Radix and Platycodi Radix containing the active ingredientsEvidence-Based Complementary and Alternative Medicine 7
Baicalin and Saponin (target herbal ingredient (THI)) was
statistically significant in its effectiveness on the weight loss
without significant side effects, which was demonstrated
by our present randomized, double-blind, and placebo-
controlled clinical trial.
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